...
首页> 外文期刊>Cancer biology & therapy >Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma.
【24h】

Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma.

机译:慢病毒介导的基因治疗通过抑制survivin抑制携带口腔鳞状细胞癌的BALB / c裸鼠。

获取原文
获取原文并翻译 | 示例
           

摘要

Despite advances in surgery, radiotherapy, and chemotherapy, the long-term survival rates with oral squamous cell carcinoma (OSCC) have not significantly improved. Gene therapy for OSCC is currently under investigation in clinical trials. Lentivirus vector is considered to be a promising gene delivery tool, but their value in cancer gene therapy has not been studied thoroughly. Survivin is overexpressed in OSCC, making it a promising target for gene therapy. This study was conducted to determine whether lentivirus-mediated gene therapy by suppressing survivin could be exploited in the treatment of OSCC. A lentivirus vector encoding short hairpin RNA (shRNA) targeting survivin was constructed and transfected into KB cells in vitro. The results showed that survivin was persistently and markedly reduced by lentivirus-mediated RNA interference (RNAi); the growth of KB cells was decreased by 34.2% on day 5; the apoptosis rate induced by vincristine (VCR) was increased by 29.8% and caspase-3 activity was also significantly increased; the IC(50) value of adriamycin (ADM) were 0.09 mug/ml, which indicated that survivin-knockout KB cells were 2.1 times more susceptible to ADM than the control; the clonogenic survival rate at 6 Gy of X ray was 3.7%, less than 15.3% of the control. In the xenograft model, the development of tumors as well as the growth of established tumors was inhibited by transfection of lentivirus. Our study indicates that lentivirus-mediated gene therapy is an attractive strategy in the treatment of OSCC and justifies the use of lentivirus in cancer gene therapy studies.
机译:尽管在外科手术,放疗和化学疗法方面取得了进步,但口腔鳞状细胞癌(OSCC)的长期生存率并未得到明显改善。 OSCC的基因治疗目前正在临床试验中进行研究。慢病毒载体被认为是一种有前途的基因递送工具,但是其在癌症基因治疗中的价值尚未得到充分研究。 Survivin在OSCC中过表达,使其成为基因治疗的有希望的靶标。进行这项研究以确定通过抑制生存素的慢病毒介导的基因疗法是否可以用于OSCC的治疗。构建了编码靶向survivin的短发夹RNA(shRNA)的慢病毒载体,并在体外转染到KB细胞中。结果表明,慢病毒介导的RNA干扰(RNAi)持续显着降低了survivin的表达。第5天,KB细胞的生长减少了34.2%;长春新碱(VCR)诱导的细胞凋亡率提高了29.8%,caspase-3活性也显着提高。阿霉素(ADM)的IC(50)值为0.09杯/毫升,这表明存活素敲除KB细胞对ADM的敏感性是对照组的2.1倍; X射线6 Gy时的克隆形成存活率为3.7%,低于对照组的15.3%。在异种移植模型中,慢病毒的转染抑制了肿瘤的发展以及已建立肿瘤的生长。我们的研究表明,慢病毒介导的基因治疗是治疗OSCC的诱人策略,它证明了慢病毒在癌症基因治疗研究中的合理使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号